Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.
Price Chart
Executive Summary
Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342336 |
| Document: enta-20260810.htm | 0001193125-26-342336 |
| Document: 0001193125-26-342336-index-headers.html | 0001193125-26-342336 |
| Document: 0001193125-26-342336-index.html | 0001193125-26-342336 |
| Document: 0001193125-26-342336.txt | 0001193125-26-342336 |
| 8-K Data (Synthetic) | 0001193125-26-342336 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access